HHS is awarding $18.5 million to two U.S.-based drug manufacturing companies to domestically produce key starting materials (KSM) and active pharmaceutical ingredients (API) necessary for essential medications, many of which were in shortage throughout 2023, a move to provide American sourcing for materials that are often produced in China. The onshoring initiative could help offset potential impacts of legislation requiring the federal government to cut ties with some Chinese biotechnology firms, which House Speaker Mike Johnson (R-LA) has vowed to...